Decompensation of distance exotropia reduces accommodation

Article

Decompensation of distance exotropia reduces accommodation, meaning it must be prevented in near vision.

Decompensation of distance exotropia reduces accommodation, meaning it must be prevented in near vision, reveals a study in the British Journal of Ophthalmology.

The investigation, led by Dr Anna Horwood, School of Psychology & Clinical Language Sciences, University of Reading, Reading, UK, consisted of 19 participants with distance exotropia. Each patient was tested using the PlusoptiXSO4 photo refractor set in a remote haploscopic device.

The refractor recorded simultaneous vergence and accommodation of a range of targets demonstrating the various combinations of blur, disparity and proximal cues. The assessments were made at four fixation distances between 2 m and 33 cm.

The study discovered that manifest exotropia was more common in the more impoverished cue conditions. The mean accommodation increase for the all-cure target was considerably reduced. The mean under-accommodation was 2.33 D at 33 cm. Blur and proximity drove residual responses when the profile of near cues usage changed after decompensation.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.